ライフサイエンスコーパス: (was|were) seen in

1 EORTC QLQ-H&N35, clinically meaningful worsening at week 15 was seen in no domains in the nivolumab group and eight (44%)

2 were adult males (68%), but the highest case fatality (39%) was seen in children aged younger than 5 years.

3 ORR of 97% and >/=VGPR 73% were seen in patients not refractory to bortezomib who had 1

4 o malignant lesions, whereas only a background accumulation was seen in control tissues.

5 In addition, radioligand accumulation was seen in primary tumor lesions as well as in metastases.

6 ins in both the photosystem I (PSI) and PSII complexes also was seen in the Rieske FeS overexpression plants.

7 isks of intraocular bleeding with novel oral anticoagulants were seen in subgroup analyses, with no significant differenc

8 For other diseases or risk factors no robust associations were seen in mothers or fathers.

9 Histological regression of BE was seen in 41% (20/49).

10 oplasia (advanced adenomas and cancer), and invasive cancer were seen in 3.8% (55 of 1429), 2.8% (40 of 1429), and 0.14%

11 No DDR2-dependent degenerative changes were seen in knees.

12 Similar but less marked changes were seen in PrP KO mice.

13 Drusen and RPE changes were seen in the peripheral retina, anterior to the vortex ve

14 disappeared from view in 58.3% of eyes, drusen coalescence was seen in 70.8% of eyes, and new RPE pigmentary changes dev

15 stratified models, associations between CA and incident CVD were seen in men (1.73 [1.12-2.67]) and not in women (1.05 [0

16 year to -1.26 g/L per year), but no significant difference was seen in the rate in early-start patients during this time

17 Potentially important differences were seen in: testing repertoire [10/44 (23%) lacked BSACI co

18 In addition, no differences were seen in objective physical function or depressive sympto

19 Significant differences were seen in delivery-related variables and associated matern

20 In the cleft region, no significant differences were seen in primary or permanent decay (dt, DT) when compare

21 Overall, no significant differences were seen in severe hypoglycaemia, pancreatitis, pancreatic c

22 Transient E2 elevation was seen in 4 of 35 (11%) with a vaginal ring and in 4 of 34

23 Ab, Abs strongly suggesting an autoimmune cause of epilepsy were seen in 23 patients (20.5%).

24 phosphorylation changes associated with activation of ERK2 were seen in PKA knockout cells.

25 Major intracranial findings were seen in only 15 of 549 (2.7%) patients, all with an indi

26 Similar findings were seen in the spinocerebellar ataxias, indicating an assoc

27 In contrast, no effect of embryo genotype was seen in concepti from heterozygous dams.

28 He was seen in consultation for management of recurrent bladder

29 cations, such as graft infection and delayed wound healing, were seen in 6 patients; 8 patients experienced severe pain.

30 of decreasing scarlet fever incidence, a dramatic increase was seen in England beginning in 2014.

31 IOP increase was seen in all 3 patients, but could be treated sufficiently

32 found at the SZ and TZ for T1 and T2*; for T1rho, increases were seen in all zones; and for T2, increases were seen at th

33 Serious adverse events within 12 months after injection were seen in 40 participants (8.0%) in the ChAd3-EBO-Z group,

34 ypic susceptibility results for both rifampin and isoniazid were seen in 26% of MTBDRplus tests performed directly on spu

35 AVA was reduced and a trend toward reduced IVNV was seen in UPI/OIR compared to control/OIR.

36 Higher frequencies of positive sIgE levels were seen in pediatric patients with AD (P < .0001).

37 cumulation, significantly better results for all parameters were seen in the probiotic group compared with the control gr

38 ary, although modest declines in neurocognitive performance were seen in single domains with statin or ACEI/ARB therapy,

39 ular abnormalities, namely ependymitis and choroid plexitis were seen in HIV- but not in HIV+ subjects.

40 1 year after HSCT, 3-month steroid-free clinical remission was seen in 13 (38%, 95% CI 22-55) of 34 patients with availa

41 With 30%, 50%, and 65% cutoffs, ETB response was seen in 60.8%, 39.2%, and 21.6% of patients, respectively

42 Similar results were seen in the comparisons between the newer biologics (e.g

43 -35) of 45 in the placebo group; adjusted IgG seroresponses were seen in 46 (98%, 89-100) of 47 infants in the 30 mug gro

44 The spot sign was seen in 29.3% of patients in phase 1, 43.1% of patients i

45 ing antibody seroresponses against the homologous Wa-strain were seen in 40 (85%, 72-94) of 47 infants in both the 30 mug

46 Similar trends were seen in outpatients aged >/=5 years and pediatric admiss

47 Seroconversion to each poliovirus type was seen in 100% of rats that received 1/40th of a human dos

48 subjects with measurable tumors, increased (18)F-FTT uptake was seen in one subject with pancreatic adenocarcinoma and an

49 Considerably less urologist-level variation was seen in the use of observation for intermediate-risk dise

50 35S promotor led to morphological changes opposite to what was seen in the transfer DNA mutants.